IP Library Granted Patent US 11,918,595
Granted Patent B2
US 11,918,595 · App. 17/669,778 · Granted Mar 5, 2024

Methods, agents, and devices for local neuromodulation of autonomic nerves

Inventors: Corinne Bright (Los Altos Hills, CA); Kondapavulur T. Venkateswara-Rao (San Jose, CA); Emily Stein (San Jose, CA)
Assignee: Tulavi Therapeutics, Inc.
A61K31/704A61K9/0019A61K31/135A61K31/445A61N1/36114
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,918,595
App. No.
17/669,778
Granted
Mar 5, 2024
Kind
B2
Abstract

Methods, agents, and devices to treat medical conditions through local chemical neuromodulation of the autonomic nervous system are described. Drug formulations may be injected at or near ganglia, nerve plexi, ganglionated plexi, and nerves to treat different diseases. Target sites for the treatment of cardiac and other disease conditions may include extrinsic stellate (cervicothoracic) and cervical ganglia of the sympathetic chain, and intrinsic cardiac nerves and ganglionated plexi innervating the myocardium.

Claims (14)

1. A method for treating a disease condition of a sympathetic nervous system in a patient, the method comprising:

delivering an agent locally to a stellate ganglion of the patient in an amount sufficient to affect function of the stellate ganglion and alleviate one or more symptoms of the disease condition in the patient, wherein the agent comprises a tricyclic antidepressant.

2. The method of claim 1 , further comprising delivering the agent in a composition comprising a PEG carrier.

3. The method of claim 1 , further comprising delivering the agent in a composition comprising a contrast agent.

4. The method of claim 1 , further comprising delivering the agent in a composition comprising a hydrogel.

5. The method of claim 1 , further comprising delivering the agent in a composition comprising a biostable polymer.

6. The method of claim 1 , further comprising delivering the agent in a composition comprising a biodegradable polymer.

7. The method of claim 1 , wherein the disease condition comprises trigeminal neuralgia.

8. The method of claim 1 , wherein the stellate ganglion is accessed via an anterior paratracheal approach.

9. The method of claim 1 , further comprising measuring electrical signals transmitted from the stellate ganglion.

10. The method of claim 9 , further comprising measuring the electrical signals transmitted from the stellate ganglion before and after delivering the agent to the stellate ganglion.

11. The method of claim 1 , wherein the stellate ganglion is accessed via a supraclavicular approach.

12. The method of claim 1 , wherein the stellate ganglion is accessed via an endovascular approach.

13. The method of claim 1 , wherein the tricyclic antidepressant comprises amitriptyline.

Assignments (4)
CHANGE OF ADDRESS Recorded Jul 26, 2022
From: TULAVI THERAPEUTICS, INC.
To: TULAVI THERAPEUTICS, INC.
Reel/Frame 060920/0833 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2022
From: BRIGHT, CORINNE; VENKATESWARA-RAO, KONDAPAVULUR T.; STEIN, EMILY
To: NORTHWIND MEDICAL, INC.
Reel/Frame 058993/0021 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2022
From: NORTHWIND MEDICAL, INC.
To: INCEPT, LLC
Reel/Frame 058993/0052 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2022
From: INCEPT, LLC
To: TULAVI THERAPEUTICS, INC.
Reel/Frame 058993/0080 →
Continuity (3)
Continuation 16076308
Provisional Application 62293327 · Feb 9, 2016
Related Publication 20220370345A1 · Nov 24, 2022
Cited By (4)
US 12,408,974 US 12,478,806 US 12,539,167 US 12,673,067